Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva’s Austedo Positioned To Compete With A Generic Rival

Executive Summary

FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.

You may also be interested in...



Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone

A Phase III trial for an extended-release subcutaneously administered version of the antipsychotic risperidone was positive in patients with schizophrenia.

Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone

Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel to evaluate in NASH, adding to its portfolio of potential metabolic disease therapies.

Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough

Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel